Foliküler Tiroid Kanseri
Özet
Foliküler tiroid kanseri (FTC), tüm vakaların yaklaşık %10'unu oluşturan ikinci en yaygın tiroid kanseri türüdür. Tiroid bezinin foliküler hücrelerinden kaynaklanan, yavaş büyüyen bir kanserdir. FTC kadınlarda erkeklere göre daha yaygındır ve sıklıkla 40 ile 60 yaşları arasında teşhis edilir. Bu kitap, teşhisten tedaviye ve uzun vadeli takibe kadar FTC'ye kapsamlı bir genel bakış sunmaktadır. Açık ve öz bir üslupla yazılmış olup hem hastalara hem de sağlık profesyonellerine yöneliktir.
Follicular thyroid cancer (FTC) is the second most common type of thyroid cancer, accounting for about 10% of all cases. It is a slow-growing cancer that arises from the follicular cells of the thyroid gland. FTC is more common in women than in men and is most often diagnosed between the ages of 40 and 60. This book provides a comprehensive overview of FTC, from diagnosis to treatment and long-term follow-up. It is written in a clear and concise style and is intended for both patients and healthcare professionals.
Referanslar
Harach HR, Escalante DA, Onativia A, Lederer Outes J, Saravia Day E, Williams ED. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol (Copenh). 1985 Jan;108(1):55–60.
Pettersson B, Adami HO, Wilander E, Coleman MP. Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. Int J Cancer. 1991 Apr 22;48(1):28–33.
Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog. 1993;4(6):615–61.
Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988 Aug 15;48(16):4459–63.
Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003 Jul;120(1):71–7.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003 Sep 1;21(17):3226–35.
Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002 Aug;87(8):3947–52.
Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005 Jun;12(2):245–62.
Cerilli LA, Mills SE, Rumpel CA, Dudley TH, Moskaluk CA. Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol. 2002 Aug;118(2):186–93.
Recommended Reporting Format for Thyroid Carcinoma Association of Directors of Anatomic and Surgical Pathology. 2000.
Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995 Dec;24(4):761–801.
Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005 Jun 1;103(11):2269–73.
Kasagi K, Takeuchi R, Miyamoto S, Misaki T, Inoue D, Shimazu A, et al. Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol (Oxf). 1994 Mar;40(3):429–34.
Bowden WD, Jones RE. Thyrotoxicosis associated with distant metastatic follicular carcinoma of the thyroid. South Med J. 1986 Apr;79(4):483–6.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994 Nov;97(5):418–28.
Mazzaferri EL, Kloos RT. CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer [Internet]. 2001. Available from: https://academic.oup.com/jcem/article/86/4/1447/2848158
Collini P, Sampietro G, Rosai J, Pilotti S. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch. 2003 Jan;442(1):71–6.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1–133.
Referanslar
Harach HR, Escalante DA, Onativia A, Lederer Outes J, Saravia Day E, Williams ED. Thyroid carcinoma and thyroiditis in an endemic goitre region before and after iodine prophylaxis. Acta Endocrinol (Copenh). 1985 Jan;108(1):55–60.
Pettersson B, Adami HO, Wilander E, Coleman MP. Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. Int J Cancer. 1991 Apr 22;48(1):28–33.
Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog. 1993;4(6):615–61.
Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988 Aug 15;48(16):4459–63.
Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003 Jul;120(1):71–7.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003 Sep 1;21(17):3226–35.
Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002 Aug;87(8):3947–52.
Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005 Jun;12(2):245–62.
Cerilli LA, Mills SE, Rumpel CA, Dudley TH, Moskaluk CA. Interpretation of RET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol. 2002 Aug;118(2):186–93.
Recommended Reporting Format for Thyroid Carcinoma Association of Directors of Anatomic and Surgical Pathology. 2000.
Grebe SK, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995 Dec;24(4):761–801.
Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005 Jun 1;103(11):2269–73.
Kasagi K, Takeuchi R, Miyamoto S, Misaki T, Inoue D, Shimazu A, et al. Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol (Oxf). 1994 Mar;40(3):429–34.
Bowden WD, Jones RE. Thyrotoxicosis associated with distant metastatic follicular carcinoma of the thyroid. South Med J. 1986 Apr;79(4):483–6.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994 Nov;97(5):418–28.
Mazzaferri EL, Kloos RT. CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer [Internet]. 2001. Available from: https://academic.oup.com/jcem/article/86/4/1447/2848158
Collini P, Sampietro G, Rosai J, Pilotti S. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma. Virchows Arch. 2003 Jan;442(1):71–6.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1–133.
